The second phase, from 2025 to 2035, will be to apply the new technologies and infrastructure to generate a complete set of pharmacological modulators for > 90% of the ~20,000 proteins encoded by the genome. “Target 2035” sounds ambitious, but its concept and practicality is on firm ground based on a number of pilot studies, which revealed the following success parameters:
* Collaborate with the pharmaceutical sector to access unparalleled expertise, experience, materials, and logistics 
* Establish clear and quantitative quality criteria for the output (target chemical tool profiles) to provide focus 
* Organize the project around protein families – it is the most efficient, practical and scientifically sound way to divide this large project into teams 
* Establish clear open science principles to eliminate or reduce conflicts of interest, to reduce legal encumbrances, and to encourage participation by the community.